Compare Novo Nordisk A/S (NVO) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs WD 40 Company — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while WD 40 Company trades at $237.72 (market cap $3.22B). The key difference: Novo Nordisk A/S is far larger — about 68.5× WD 40 Company's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | WDFC | |
|---|---|---|
Market Cap | $220.53B | $3.22B |
Sector | Health | Technology |
52-Week High | $71.70 | $264.91 |
52-Week Low | $35.29 | $187.52 |
Enterprise Value | $239.49B | $3.27B |
Dividend Yield | 3.63% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
WDFC trades at $239.59, down 2.92% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, and maintains solid profitability with a 13.22% net income margin. Recent news highlights its brand strength and efficient operations, though some analysts see limited upside.
The outlook is balanced: earnings beats and a strong brand provide support, but high valuation multiples (P/E 36.44) and mixed analyst sentiment (71.42% hold rating) suggest cautious optimism. Key risks include margin pressure from input costs and competitive challenges, requiring careful monitoring of future earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
